🔗 Share this article

As America proceeds with sweeping adjustments to its vaccine schedules, one figure appears unexpectedly: Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who rose to prominence by questioning coronavirus shots throughout the global health crisis and has concentrated on possible fatalities following Covid immunization in her recent position at the Food and Drug Administration.

Scheduled Changes to Childhood Immunization Schedule

Health officials were set to announce major revisions to the childhood immunization program recently, bringing the US with the Danish immunization schedule, it is understood – a significant shift that would place the US at odds with much of the international standard with insufficient data for public health gain. The announcement has been postponed until the next year.

In place of Vinay Prasad, Dr. Høeg is scheduled to present at the gathering. She was just designated acting director of the FDA’s CDER, the fifth appointee to lead the office this calendar year.

A New Direction at the FDA

Høeg's temporary position might represent a strengthened alliance between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad solidify control at the agency – and it signals a greater focus upon reevaluating previously authorized immunizations at the FDA.

The new acting director has frequently advocated for ending certain pediatric immunization guidelines in the US in order to be more similar to Denmark, a country with universal health coverage and a population about the size of the state of Wisconsin.

So far comments, she has continued to focus on vaccines – usually the domain of Prasad, head of the FDA’s CBER – rather than pharmaceutical oversight.

Questions Over Expertise

Høeg has little discernible background in drug development, oversight or administrative roles, which has been customary for previous heads of the biologics center. She has served at the FDA as a key advisor to the FDA chief and CBER since spring.

“It seems she lacks to have the necessary background” for running the drug-regulation department, stated a neurologist and psychiatrist. “She has not conducted a scientific study. She is not versed in managing a large organization. She has no expertise in industry regulation.”

Previous directors of the center would “grasp legal statutes and the underlying principles of medication creation”, said a former acting FDA commissioner. “Clearly, she has not acquired the kind of background that previous people who ran the center have had.”

CDER has an immense range of responsibilities at the FDA, the former commissioner emphasized.

“Many people just pays attention on the innovative therapies, but the generic program clears numerous off-brand pharmaceuticals. There’s a biologic copycat branch, OTC medication office and more, and every single one have to be supervised,” she noted. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Additionally, a significant leadership component to the job, which supervises more than 5,000 staff members. “It is a massive administrative position, if you execute it properly,” the former official concluded.

Response and Contentious Programs

When asked about questions about Dr. Høeg's qualifications and whether this assignment indicates increased cooperation among agency officials on vaccines, a press secretary responded that the “inquiries are based on flawed assumptions”.

“Her resume matches the responsibilities of her role,” the representative stated, pointing to the months Dr. Høeg spent advising the agency head on “medication safety and approval science, including computational safety modeling and shot safety tracking”.

In her interim role, Høeg takes over the commissioner’s new fast-track approval initiative, a disputed one-day therapy clearance system that reportedly worried her former heads. “By what process are these drugs being selected for this voucher program? Who makes the choices?” Dr. Howard asked. “There’s a lot of secrecy happening at the FDA right now.”

Broadly speaking, he said, “the FDA looks to be trending towards less stringent regulations of pharmaceuticals, aside from shots.”

Public History on Immunizations

Concerning immunizations, Høeg has a more established, if troubling, past, some experts have noted. She published a analysis using non-validated public submissions to determine the incidence of heart inflammation following COVID-19 vaccination. She counseled the Florida chief medical officer Joseph Ladapo, who was said to have altered data to imply COVID-19 vaccinations are more dangerous than they are.

Included in her “policy goals” for the incoming administration featured revising rules for recently developed shots and ending “unnecessary” immunizations, she said following the vote on a online show. At the agency, Dr. Høeg has allegedly suggested preventing teenage boys from obtaining COVID-19 vaccinations.

“She is an complete true believer who begins with her preconceived notions and tailors the evidence to retrofit the evidence in a very disingenuous, dishonest manner,” Dr. Howard said.

Taking Control and a “Push for Payback”

Høeg became part of fellow skeptics, {like|